| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
S-Nitrosated human serum albumin (SNO-HSA) is useful in preventing liverischemia/reperfusion injury, and SNO-HSA should thus be able to prevent cell injury duringliver transplantation. However, the potential protective effect of SNO-HSA on acombination of cold and warm ischemia, which is obligatory when performing livertransplantation, has not been examined. Our results indicate that a combination of SNO-HSAand UW solution can be used to prevent the two types of ischemia. Therefore, SNO-HSA-addedUW solution could be very useful in transplantation, because the previously imposedconstraints on preservation time can be removed. This is a great advantage in a situationas the present one with increased utilization of scarce donor organs for more recipients
|
